Name: UMIN ID:
Unique ID issued by UMIN | UMIN000014243 |
---|---|
Receipt number | R000016585 |
Scientific Title | Randomized controlled study of GnRH antagonist monotherapy and CAB with GnRH agonist plus bicalutamide for patients with metastatic prostate cancer. |
Date of disclosure of the study information | 2014/06/12 |
Last modified on | 2020/12/15 09:54:55 |
No. | Disposal | Last modified on | Item of update | |
---|---|---|---|---|
1 | Insert | 2014/06/12 10:06:13 | ||
2 | Update | 2014/06/12 10:13:44 | Key inclusion criteria |
|
3 | Update | 2014/12/15 15:48:34 | Recruitment status |
|
4 | Update | 2015/06/15 09:18:43 | Organization Organization Division name Division name Address Address TEL |
|
5 | Update | 2016/06/13 09:43:16 | Name of primary person or sponsor Organization Institutions |
|
6 | Update | 2017/12/14 09:43:39 | Recruitment status Last follow-up date |
|
7 | Update | 2018/06/14 09:18:59 | Organization Organization Division name Division name Address Address TEL |
|
8 | Update | 2019/01/10 10:40:09 | Interventions/Control_2 Key inclusion criteria Key inclusion criteria |
|
9 | Update | 2019/01/10 10:40:30 | Last follow-up date |
|
10 | Update | 2019/01/11 14:26:44 | Public title Acronym |
|
11 | Update | 2019/01/11 14:27:34 | Developmental phase |
|
12 | Update | 2019/01/11 14:29:57 | Organization1 |
|
13 | Update | 2019/06/26 16:22:45 | 1st name of lead principal investigator Last name of lead principal investigator 1st name of lead principal investigator Last name of lead principal investigator Zip code Address Last name of contact person Last name of contact person Zip code Address Organization Organization Address Address Tel |
|
14 | Update | 2019/06/26 16:23:35 | Number of participants that the trial has enrolled |
|
15 | Update | 2019/06/26 16:25:26 | Date of IRB |
|
16 | Update | 2020/06/18 09:24:43 | Last follow-up date |
|
17 | Update | 2020/12/15 09:54:55 | Recruitment status Date trial data considered complete Date analysis concluded |